AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

 

• Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain
• Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics

https://www.prnewswire.com/news-releases/abbvie-to-acquire-nimble-therapeutics-further-strengthening-immunology-pipeline-302331351.html